导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -16.69% | 4176/4773 |
| 近一周 | -6.57% | 5380/5462 |
| 近一月 | -5.89% | 3381/5421 |
| 近一季 | -3.54% | 1428/5209 |
| 近半年 | -21.00% | 4424/4920 |
| 近一年 | -20.37% | 3943/4366 |
| 近两年 | 42.85% | 1746/2954 |
| 近三年 | 11.82% | 1703/2253 |
| 成立以来 | -61.93% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.41% 1789/4961 |
-15.70% 4694/5312 |
- - |
- - |
| 2025 | 28.38% 1487/4813 |
5.79% 730/3635 |
5.00% 666/4076 |
22.15% 1684/4524 |
-5.39% 3551/4813 |
| 2024 | 8.08% 1588/3463 |
2.09% 818/2808 |
-16.24% 2723/3014 |
20.50% 708/3129 |
4.89% 660/3463 |
| 2023 | 22.88% 13/2656 |
39.08% 29/2280 |
6.92% 37/2385 |
-12.56% 2122/2515 |
-5.50% 1376/2655 |
| 2022 | -27.68% 1499/2207 |
-20.78% 1573/1919 |
-3.10% 1799/2016 |
-16.76% 1493/2113 |
13.19% 107/2208 |
| 2021 | 3.37% 613/1822 |
-7.90% 1069/1255 |
2.61% 994/1330 |
-10.67% 1234/1466 |
22.44% 17/1822 |
| 2020 | 1.27% 934/1250 |
-5.97% 448/1028 |
17.88% 357/1067 |
0.81% 1037/1164 |
-9.36% 1161/1184 |
| 2019 | 27.67% 536/1092 |
32.94% 156/754 |
-16.13% 786/804 |
3.42% 253/850 |
10.72% 104/918 |
| 2018 | -33.93% 559/834 |
- - |
- - |
- - |
-7.41% 63/691 |
| 2017 | -25.67% 585/714 |
- - |
- - |
- - |
- - |
| 2016 | -31.84% 509/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 工银传媒指数A VS. 长安沪深300非周期A(740101) |